Amicus Therapeutics, Inc. (NASDAQ:FOLD) saw a large decrease in short interest in the month of September. As of September 29th, there was short interest totalling 31,216,474 shares, a decrease of 10.0% from the September 15th total of 34,667,755 shares. Based on an average daily volume of 4,218,265 shares, the days-to-cover ratio is presently 7.4 days. Currently, 19.6% of the company’s shares are sold short.

Amicus Therapeutics (NASDAQ FOLD) opened at 14.53 on Monday. The company has a 50 day moving average price of $14.39 and a 200 day moving average price of $10.90. Amicus Therapeutics has a 12 month low of $4.41 and a 12 month high of $16.60. The stock’s market capitalization is $2.39 billion.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.03. Amicus Therapeutics had a negative net margin of 1,279.88% and a negative return on equity of 61.25%. The business had revenue of $7.16 million for the quarter, compared to analysts’ expectations of $6.96 million. During the same period in the previous year, the company posted ($0.40) EPS. Equities research analysts predict that Amicus Therapeutics will post ($1.32) earnings per share for the current year.

A number of research analysts have weighed in on the company. J P Morgan Chase & Co reissued an “overweight” rating on shares of Amicus Therapeutics in a research note on Wednesday, October 4th. Robert W. Baird reissued an “outperform” rating and set a $18.00 price target (up previously from $16.00) on shares of Amicus Therapeutics in a research note on Wednesday, October 4th. Chardan Capital reissued a “buy” rating and set a $18.50 price target (up previously from $16.50) on shares of Amicus Therapeutics in a research note on Thursday, October 5th. Goldman Sachs Group, Inc. (The) reissued a “neutral” rating and set a $17.00 price target on shares of Amicus Therapeutics in a research note on Friday, October 6th. Finally, Leerink Swann reissued a “buy” rating and set a $20.00 price target (up previously from $17.00) on shares of Amicus Therapeutics in a research note on Wednesday, October 4th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $17.81.

Several institutional investors have recently bought and sold shares of the company. Bank of Nova Scotia purchased a new position in shares of Amicus Therapeutics during the 2nd quarter valued at $1,944,000. Redmile Group LLC grew its holdings in shares of Amicus Therapeutics by 5.9% during the 2nd quarter. Redmile Group LLC now owns 12,043,932 shares of the biopharmaceutical company’s stock valued at $121,282,000 after acquiring an additional 668,080 shares in the last quarter. State Street Corp grew its holdings in shares of Amicus Therapeutics by 2.2% during the 2nd quarter. State Street Corp now owns 5,892,564 shares of the biopharmaceutical company’s stock valued at $59,332,000 after acquiring an additional 125,635 shares in the last quarter. Gotham Asset Management LLC purchased a new position in shares of Amicus Therapeutics during the 2nd quarter valued at $308,000. Finally, Palo Alto Investors LLC grew its holdings in shares of Amicus Therapeutics by 0.7% during the 2nd quarter. Palo Alto Investors LLC now owns 7,940,788 shares of the biopharmaceutical company’s stock valued at $79,964,000 after acquiring an additional 57,800 shares in the last quarter.

ILLEGAL ACTIVITY WARNING: “Amicus Therapeutics, Inc. (FOLD) Short Interest Update” was originally published by Watch List News and is owned by of Watch List News. If you are viewing this story on another domain, it was stolen and reposted in violation of US & international copyright and trademark law. The legal version of this story can be read at https://www.watchlistnews.com/amicus-therapeutics-inc-fold-short-interest-update/1633418.html.

About Amicus Therapeutics

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.